Holen Sie sich die Stockscreener-App
3.60
1.91%
-0.07
Handel nachbörslich:
3.60
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.67
Offen:
$3.65
24-Stunden-Volumen:
1.78M
Relative Volume:
0.33
Marktkapitalisierung:
$291.99M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.1951
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-1.37%
1M Leistung:
-24.37%
6M Leistung:
-47.90%
1J Leistung:
-39.14%
1-Tages-Spanne:
$3.535
$3.65
1-Wochen-Bereich:
$3.535
$3.77
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.60 | 297.66M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | -1.26B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit - GlobeNewswire
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Investor Alert: Deadline Approaching to Join Altimmune, Inc. (ALT) Class ActionContact Levi & Korsinsky - Newsfile
Altimmune, Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Altimmune Faces Legal Storm as Trial Results Disappoint - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Morningstar
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - PR Newswire
Altimmune Inc. stock momentum explainedPrice Forecast Based on AI Analysis - Newser
Order flow analysis tools used on Altimmune Inc.Entry Confirmation Using Short-Term Forecasting - Newser
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Altimmune, Inc. Securities and Sets a Lead Plaintiff Deadline of October 6, 2025 - Business Upturn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
What makes Altimmune Inc. stock attractive to long term investorsFree Triple Return Setup with Risk Control - Newser
Altimmune reports Q2 2025 financial results on August 12. - AInvest
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | ALT Stock News - GuruFocus
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - The Manila Times
Why Altimmune Inc. stock attracts strong analyst attentionFree Weekly Return Pick Forecast Reports - Newser
Clinical-Stage Biotech Altimmune Sets Q2 2025 Earnings DateKey Details for Investors - Stock Titan
Analyzing recovery setups for Altimmune Inc. investorsFree Access to Smart Investment Tips - Newser
Levi & Korsinsky Investigates Altimmune, Inc. (ALT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Market reaction to Altimmune Inc.’s recent newsTechnical Insight Guide for Safer Trades - Newser
Published on: 2025-08-04 04:35:56 - Newser
Should I hold or sell Altimmune Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What are Altimmune Inc. company’s key revenue driversExtraordinary profit generation - Jammu Links News
Does Altimmune Inc. stock perform well during market downturnsRapid portfolio appreciation - Jammu Links News
What makes Altimmune Inc. stock price move sharplyCapitalize on high-growth stocks early - Jammu Links News
Is Altimmune Inc. a good long term investmentDynamic profit opportunities - Jammu Links News
Protect Your Investment: Contact Levi & Korsinsky About the Altimmune, Inc. (ALT) Investigation - ACCESS Newswire
What catalysts could drive Altimmune Inc. stock higher in 2025Unlock powerful trading signals and alerts - Jammu Links News
How volatile is Altimmune Inc. stock compared to the marketCapitalize on momentum-driven stocks - jammulinksnews.com
How strong is Altimmune Inc. company’s balance sheetDiscover stocks with superior performance - Jammu Links News
Is Altimmune Inc. stock overvalued or undervaluedAchieve superior returns through strategic trading - Jammu Links News
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Altimmune Inc. stock performs during market volatilityReal Time Stock Movement and Alerts - Newser
Applying chart zones and confluence areas to Altimmune Inc.High Reward Picks with Tight Risk Control - Newser
What institutional investors are buying Altimmune Inc. stockFree Stock Data Feed Backed By Experts - Jammu Links News
Altimmune, Inc. (ALT) Stock Analysis: Exploring The 376.96% Potential Upside - DirectorsTalk Interviews
Is Altimmune Inc. reversing from oversold territorySafe Momentum Strategy With Trend Analysis - Newser
What is the risk reward ratio of investing in Altimmune Inc. stockExpert Picks Insights For Fast Growth - Jammu Links News
Altimmune Bets Big On Next-Gen Obesity And Liver Drugs - Finimize
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Published on: 2025-07-31 05:27:57 - Newser
How to use a screener to detect Altimmune Inc. breakoutsTechnical Reversal Pattern Summary and Tracker - Newser
Altimmune Inc. stock daily chart insightsGrowth Based Investment Plan Guidance Highlighted - metal.it
How sentiment analysis helps forecast Altimmune Inc.Chart Pattern Recognition for Profit Timing - Newser
Regression analysis insights on Altimmune Inc. performanceWeekly Chart-Based Forecast for Traders - Newser
Is Altimmune Inc. stock reversal real or fakeEntry Opportunity Screener with Confirmation - Newser
Altimmune, Inc. Securities Lawsuit Investigation - Claim Depot
Real Time Data Flags Unusual Activity in Altimmune Inc.Oversold Bounce Stock Play Ideas Gain Attention - beatles.ru
ALT Investor Notice: Levi & Korsinsky Investigates Altimmune, Inc. For Securities Law Violations - ACCESS Newswire
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):